Polypharmacy in Psychiatry Practice, Volume II: Use of Polypharmacy in the Real World

ISBN-13: 9789400757981 / Angielski / Twarda / 2013 / 321 str.

Michael S. Ritsner

Opis

Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.

Recenzje

From the reviews:

"The intent is to bring together a compendium of information from both clinical research and experience regarding the ever-increasing use of polypharmacy in the treatment of psychiatric conditions. ... should be read by anyone involved in the pharmacological management of psychiatric illnesses." (Michael Easton, Doody's Book Reviews, July, 2013)

Spis treści

About the Editor

Preface 

Contributors to Volume II

Part 1. Antipsychotic polypharmacy  

1.      Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'? Peter F. Buckley

2.      Antipsychotic polypharmacy in USA.  Anand K. Pandurangi, John Vernon

3.      Antipsychotic polypharmacy in Czech Republic and in Ukraine. Viktor P. Samokhvalov, Oxana Samokhvalova, Viktoria  A. Verbenko, Georgij N. Verbenko

4.      Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice. Lucio Ghio, Werner Natta, Simona Gotelli, Luigi Ferrannini

5.      Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational? KH Yong, Norman Sartorius, Kang Sim

6.      Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice? Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Masaru Mimura

7.      Clozapine combinations in treatment-resistant schizophrenia patients. Vladimir Lerner and Chanoch Miodownik

8.      Metabolic syndrome and antipsychotic polypharmacy. Fuminari Misawa, Fujii Yasuo, Yasuyuki Okumura, Hiroto Ito

 

Part 2. Polypharmacy for other psychiatric conditions

9.      Evidence based combination therapy for bipolar disorder. Stamatia Magiria, Melina Siamouli, Xenia Gonda, Apostolos Iacovides, Konstantinos N. Fountoulakis

10.  Antidepressant combination strategies for major depressive disorder. André F. Carvalho, Danielle S. Macêdo, Thomas N. Hyphantis, Roger S. McIntyre

11.  Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk. Arun V. Ravindran and Tricia L. da Silva

12.  Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy? Frederike Schirmbeck and Mathias Zink

13.  Polypharmacy and potentially inappropriate medication use among elders with dementia. Jan Lužný

14.  The role of polypharmacy in bipolar disorder treatment guidelines. Heinz Grunze

Appendix             Rena Kurs

1.      Annotated bibliography on polypharmacy

2.      List of Psychotropic Medications  

Contents to Volume I

Contributors to Volume I

Index

Blurb

Despite the large number of psychotropic medications currently available, effective management of mental disorders continues to be a challenging task. Although monotherapy may be desirable, most patients require combinations of two or more psychotropic drugs. Polypharmacy aims to address different aspects of treatment resistance, especially insufficient response of positive and negative symptoms, cognitive disturbances, affective comorbidity, obsessive-compulsive syndromes and side-effects of antipsychotic agents. At the same time, evidence based guidelines in support of polypharmacy, and augmentative strategies are scant.

This two-volume collection is the first comprehensive, clinically oriented, reference text on polypharmacy (co-administration of more than one medication) or the use of multiple preparations to treat psychotic, cognitive, mood and anxiety disorders. This collection is divided into four parts.

Volume I contains two parts including chapters that serve as an introduction and overview of conceptual issues. Key topics include: rational polypharmacy, receptor binding targets, drug interactions, preclinical and clinical investigations in this field, dosing regimens, multiple medication use in forensic psychiatry, a naturalistic trial, adjunctive strategies, and multiple medication use for the treatment of somatic symptom disorders.

Volume II contains two parts that focus on antipsychotic polypharmacy for schizophrenia, and clinical practice in the USA, Czech Republic, Ukraine, and Italy, polypharmacy and associated phenomena, clozapine combinations and the metabolic syndrome. The authors discuss combination therapy for bipolar disorder, major depressive disorder, obsessive-compulsive syndromes in schizophrenia, and potentially inappropriate medication use among elderly patients with dementia.

Finally, each volume includes Appendix contains ‘Annotated bibliography on polypharmacy’ and ‘List of Psychotropic Medications’.